Genedx Holdings Corp Stock Alpha and Beta Analysis
| WGS Stock | 78.71 6.64 9.21% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as GeneDx Holdings Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in GeneDx Holdings over a specified time horizon. Remember, high GeneDx Holdings' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to GeneDx Holdings' market risk premium analysis include:
Beta 0.63 | Alpha 1.28 | Risk 7.59 | Sharpe Ratio 0.2 | Expected Return 1.49 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
GeneDx |
GeneDx Holdings Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. GeneDx Holdings market risk premium is the additional return an investor will receive from holding GeneDx Holdings long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in GeneDx Holdings. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate GeneDx Holdings' performance over market.| α | 1.28 | β | 0.63 |
GeneDx Holdings expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of GeneDx Holdings' Buy-and-hold return. Our buy-and-hold chart shows how GeneDx Holdings performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.GeneDx Holdings Market Price Analysis
Market price analysis indicators help investors to evaluate how GeneDx Holdings stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading GeneDx Holdings shares will generate the highest return on investment. By understating and applying GeneDx Holdings stock market price indicators, traders can identify GeneDx Holdings position entry and exit signals to maximize returns.
GeneDx Holdings Return and Market Media
The median price of GeneDx Holdings for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 54.33 with a coefficient of variation of 31.93. The daily time series for the period is distributed with a sample standard deviation of 16.82, arithmetic mean of 52.69, and mean deviation of 14.79. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 717 shares by Kevin Feeley of GeneDx Holdings subject to Rule 16b-3 | 08/30/2024 |
2 | Disposition of 262 shares by Kevin Feeley of GeneDx Holdings at 31.7096 subject to Rule 16b-3 | 09/03/2024 |
3 | Dovetail Genomics Showcases New VariLink Assay Findings at AGBT Conference | 09/04/2024 |
4 | Disposition of 6546 shares by Katherine Stueland of GeneDx Holdings subject to Rule 16b-3 | 09/09/2024 |
5 | Disposition of 2635 shares by Kevin Feeley of GeneDx Holdings at 37.59 subject to Rule 16b-3 | 09/16/2024 |
6 | GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 | 10/03/2024 |
7 | Disposition of 130 shares by Ruch Joshua of GeneDx Holdings subject to Rule 16b-3 | 10/15/2024 |
8 | GeneDx Shares Skyrocket 50 percent Today on Profit Milestone and Surge in Genomic Growth | 10/29/2024 |
9 | GeneDx Holdings Corp Shares Gap Down to 77.44 on Nov 1 | 11/01/2024 |
10 | GeneDx to Highlight Key Research Findings at American Society of Human Genetics Annual Meeting | 11/04/2024 |
11 | Zacks.com featured highlights include Snap, GeneDx and Leonardo | 11/05/2024 |
12 | GeneDx Holdings Corp Stock Price Up 5.28 percent on Nov 8 | 11/08/2024 |
13 | 40,573 Shares in GeneDx Holdings Corp. Acquired by Chartwell Investment Partners LLC | 11/13/2024 |
14 | Disposition of tradable shares by Katherine Stueland of GeneDx Holdings at 74.3389 subject to Rule 16b-3 | 11/15/2024 |
15 | GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover | 11/19/2024 |
16 | GeneDx CEO Katherine Stueland sells 3.2m in stock | 11/20/2024 |
17 | Katherine Stueland Sells 22,307 Shares of GeneDx Holdings Corp. Stock | 11/21/2024 |
About GeneDx Holdings Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including GeneDx or other stocks. Alpha measures the amount that position in GeneDx Holdings Corp has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 5.12 | 5.68 | 13.86 | 14.56 | Days Of Inventory On Hand | 53.37 | 19.08 | 22.57 | 40.43 |
GeneDx Holdings Upcoming Company Events
As portrayed in its financial statements, the presentation of GeneDx Holdings' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, GeneDx Holdings' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of GeneDx Holdings' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of GeneDx Holdings. Please utilize our Beneish M Score to check the likelihood of GeneDx Holdings' management manipulating its earnings.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with GeneDx Holdings
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for GeneDx Stock Analysis
When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.